Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab + olaparib for HRD advanced colorectal cancer
2021-003767-10Phase 2Active
- Sponsor
- GEMCAD
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and olaparib in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by GEMCAD. Primary endpoint: Objective response rate. Started Jan 2022; status: active.
02
Drugs
pembrolizumabolaparib
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2021-003767-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003767-10.